P1427ROLE OF ETECALCETIDE IN THE MANAGEMENT OF SECUNDARY HYPERPARATHYROIDISM
Sign Up to like & getrecommendations! Published in 2020 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfaa142.p1427
Abstract: Secondary Hyperparathyroidism (SHPT) is a complication of chronic kidney disease (CKD). Etelcalcetide is the first intravenous calcimimetic authorized for the treatment of SHPT in haemodialysis (HD). It has proven to be effective in lowering parathyroid… read more here.
Keywords: calcium binders; received etelcalcetide; group; non calcium ... See more keywords